Validated LC‐MS/MS method of Sphingosine 1‐phosphate quantification in human serum for evaluation of response to radiotherapy in lung cancer
Open Access
- 31 March 2020
- journal article
- research article
- Published by Wiley in Thoracic Cancer
- Vol. 11 (6), 1443-1452
- https://doi.org/10.1111/1759-7714.13409
Abstract
Background Sphingosine 1‐phosphate (S1P), a bioactive lipid, has been shown to mediate cancer processes. Therefore, accurate qualitative and quantitative determination is essential. The current assay method is still cumbersome to be of practical use worldwide and the aim of this study was therefore to develop a fast, accurate, precise and efficient LC‐MS/MS method for targeted analyses of S1P in serum samples. Methods Liquid chromatography‐tandem mass spectrometry (LC‐MS/MS) is an established method used for monitoring and analyzing S1P levels in serum. We determined the level of serum S1P in 256 patients with lung cancer and 36 healthy donors, and used Spearman';s rank correlation analysis to evaluate the difference in serum S1P levels between radiotherapy and nonradiotherapy patients. Results Standard curves were linear over ranges of 25–600 ng/mL for S1P with correlation coefficient (r2) greater than 0.9996. The lower limit of quantifications (LLOQs) was 25 ng/mL. The intra‐ and interbatch precisions and accuracy was less than 10% for S1P. The recoveries of the method were found to be 80%–98%. Serum S1P levels in healthy donors were different from those in patients (P < 0.001). Of 256 lung cancer patients, 124 (48.4%) received radiotherapy and were identified to have concomitant low serum S1P levels (222.13 ± 48.63), whereas 132 (51.6%) who had not received radiotherapy were identified to have high levels (315.16 ± 51.06). The serum S1P levels were therefore associated with radiotherapy (Spearman's Rho = −0.653, P < 0.001). Conclusions Our results indicated that this new LC‐MS/MS method is rapid, sensitive, specific and reliable for the quantification of S1P levels in serum samples. The level of S1P in serum samples of patients with lung cancer who received radiotherapy was significantly lower than that in patients who did not receive radiotherapy. Key points An improved method was established to quantify S1P levels in human serum by LC‐MS/MS, which enabled the change in serum S1P levels in lung cancer patients to be monitored, in combination with radiotherapy, and their clinical significance to be analyzed.Keywords
Funding Information
- Medicine and Health Science Technology Development Program of Shandong Province (2017WSA18034)
- Shandong Province Key Research Development Program (2018GSF118175)
This publication has 29 references indexed in Scilit:
- ABC294640, a sphingosine kinase 2 inhibitor, enhances the antitumor effects of TRAIL in non-small cell lung cancerCancer Biology & Therapy, 2015
- Simultaneous Quantification of Sphingolipids in Small Quantities of Liver by LC-MS/MSMass Spectrometry, 2014
- Simultaneous determination of sphingosine and sphingosine 1-phosphate in biological samples by liquid chromatography–tandem mass spectrometryJournal of Chromatography B, 2011
- Roles of sphingosine 1-phosphate on tumorigenesisWorld Journal of Biological Chemistry, 2011
- The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNMAnnals of Surgical Oncology, 2010
- Vascular Endothelium As a Contributor of Plasma Sphingosine 1-PhosphateCirculation Research, 2008
- LC–MS/MS-analysis of sphingosine-1-phosphate and related compounds in plasma samplesProstaglandins & Other Lipid Mediators, 2006
- Mechanism of action of sphingolipids and their metabolites in the toxicity of fumonisin B1Progress in Lipid Research, 2005
- Sphingosine 1-phosphate and ceramide 1-phosphate: expanding roles in cell signalingJournal of Cell Science, 2005
- Enzymatic Measurement of Sphingosine 1-PhosphateAnalytical Biochemistry, 1999